Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
MacroGenics applies its understanding of disease biology, immune-mediated mechanisms and protein engineering capabilities to design specifically targeted antibody-based product candidates that leverage third-party proprietary linker payloads to drive selective killing.
MacroGenics has extensive experience applying its proprietary multi-specific DART and TRIDENT platforms to develop molecules that redirect T-cell activation and killing which: (1) recognize and bind to structures expressed on a cancer cell, (2) recruit all types of cytotoxic, or cell killing, T cells, irrespective of their ability to recognize cancer cells, and (3) trigger T cell activation, expansion, and cell killing mechanisms to destroy a cancer cell.
MacroGenics’ next-generation T-cell engagers incorporate a CD3 component that is designed to minimize cytokine-release syndrome (CRS), a potentially life-threatening toxicity, while increasing the magnitude of antitumor activity with a longer half-life to permit intermittent dosing.